MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.

ABSTRACT:

Introduction

Correct risk assessment of disease recurrence in patients with early breast cancer is critically important to detect patients who may be spared adjuvant chemotherapy. In clinical practice this is increasingly done based on the results of gene expression assays. In the present study we compared the concordance of the 70-gene signature MammaPrint (MP) with the 12 gene assay EndoPredict (EP).

Methods

Representative tissue of 48 primary tumours was analysed with the MP during routine diagnostic purposes. Corresponding formalin-fixed, paraffin-embedded tissue was thereafter analysed by the EP test. Risk categories of both tests were compared.

Results

41 of 48 tumours could be directly compared by both tests. Of the 17 MP low risk cases, only 9 were considered

SUBMITTER: Bosl A 

PROVIDER: S-EPMC5574574 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature